The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 3, 2012, Pages 227-237

  Tai, Leon M ^a,b   Jacobsen, Helmut ^a   Ozmen, Laurence ^a   Flohr, Alexander ^a   Jakob Roetne, Roland ^a   Caruso, Antonello ^a   Grimm, Hans Peter ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Amyloid beta; Gamma secretase inhibitor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; GAMMA SECRETASE INHIBITOR; N [2 FLUORO 6 METHYL 8 OXO 9 (2,2,2 TRIFLUOROETHYL) 6,7,8,9 TETRAHYDRO 5 OXA 9 AZA BENZOCYCLOHEPTEN 7 YL] 2 HYDROXY 2 METHYL N' (2,2,2 TRIFLUOROETHYL)MALONAMIDE; RO 5036450; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; IC 50; IN VITRO STUDY; NONHUMAN; OLFACTORY BULB; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN LOCALIZATION; PROTEIN METABOLISM; RAT; SOLID PHASE EXTRACTION; WILD TYPE;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; MALE; MODELS, BIOLOGICAL; PROTEASE INHIBITORS; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84865511245     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9246-4     Document Type: Article

References (32)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353-356
2. Xu X (2009) Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. J Alzheimers Dis 16(2): 211-224
3. Tomita T (2009) Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother 9(5):661-679
4. Jakob-Roetne R, Jacobsen H (2009) Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl 48(17):3030-3059
5. Abramowski D et al (2008) Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 327(2):411-424
6. Anderson JJ et al (2005) Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 69(4):689-698
7. Barten DM et al (2005) Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 312(2):635-643
8. Bateman RJ et al (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66(1):48-54
9. Best JD et al (2006) In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gammasecretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5- difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) in the rat. J Pharmacol Exp Ther 317(2):786-790
10. Best JD et al (2005) Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2- hydroxyethanoyl]-N1-[(7S)- 5-methyl-6-ox o-6,7-dihydro-5H-dibenzo[b, d]azepin-7-yl]-Lalaninamide]. J Pharmacol Exp Ther 313(2):902-908
11. Best JD et al (2007) The novel gamma secretase inhibitor N-[cis- 4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]- 1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 320(2):552-558
12. Cirrito JR et al (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloidbeta metabolism and half-life. J Neurosci 23(26):8844-8853
13. Dovey HF et al (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76(1): 173-181
14. Lanz TA et al (2004) Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2- (3,5-difluorophenyl)-2-hydroxyethanoyl]- N1-[(7S)-5-methyl-6- oxo -6,7-dihydro-5H-dibenzo[b, d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther 309(1):49-55
15. Lanz TA et al (2006) Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 319(2):924-933
16. Cirrito JR et al (2005) P-glycoprotein deficiency at the bloodbrain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115(11):3285-3290
17. Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56(4):406-419
18. Sheiner LB (1984) The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 15(1-2):153-171
19. Flohr A, Jakob-Roetne R, Wostl W (2006) WO 2006/061136
20. El Mouedden M et al (2005) Method for the determination of the levels of beta-amyloid peptide in the CSF sampled from freely moving rats. J Pharmacol Toxicol Methods 52(2):229-233
21. Lanz TA, Schachter JB (2006) Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-beta from wild-type rodent brain. J Neurosci Methods 157(1):71-81
22. Lanz TA, Schachter JB (2008) Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies. J Neurosci Methods 169(1):16-22
23. Brockhaus M et al (1998) Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. NeuroReport 9(7):1481-1486
24. Shibata M et al (2000) Clearance of Alzheimer's amyloidss (1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106(12):1489-1499
25. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093-1095
26. Preston JE (2001) Ageing choroid plexus-cerebrospinal fluid system. Microsc Res Tech 52(1):31-37
27. Bijsterbosch MK et al (1981) The plasma volume of the Wistar rat in relation to the body weight. Experientia 37(4):381-382
28. Kandimalla KK et al (2005) Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP, PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther 313(3):1370-1378
29. Shiiki T et al (2004) Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci 24(43):9632-9637
30. Marques MA et al (2009) Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system. J Alzheimers Dis 16(2):325-329
31. Poduslo JF et al (1997) Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier. Neurobiol Dis 4(1):27-34
32. Kang JE et al (2009) Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326(5955):1005-1007